JPH07228539A - Extrct from leaf lagerstroemia speciosa and antidiabetic agent - Google Patents

Extrct from leaf lagerstroemia speciosa and antidiabetic agent

Info

Publication number
JPH07228539A
JPH07228539A JP6021510A JP2151094A JPH07228539A JP H07228539 A JPH07228539 A JP H07228539A JP 6021510 A JP6021510 A JP 6021510A JP 2151094 A JP2151094 A JP 2151094A JP H07228539 A JPH07228539 A JP H07228539A
Authority
JP
Japan
Prior art keywords
extract
organic solvent
fraction
leaf
adsorbed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP6021510A
Other languages
Japanese (ja)
Other versions
JP3507115B2 (en
Inventor
Takami Tsunoda
隆巳 角田
Iwao Sakane
巌 坂根
Takanori Takihara
孝宣 瀧原
Toshio Kawasaki
年夫 川崎
Hisanao Takeuchi
久直 竹内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ITOUEN KK
Ito En Ltd
Original Assignee
ITOUEN KK
Ito En Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ITOUEN KK, Ito En Ltd filed Critical ITOUEN KK
Priority to JP02151094A priority Critical patent/JP3507115B2/en
Publication of JPH07228539A publication Critical patent/JPH07228539A/en
Application granted granted Critical
Publication of JP3507115B2 publication Critical patent/JP3507115B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE:To obtain an antidiabetic agent, containing a specific fraction of an extract from a leaf of Lagerstroemia speciosa as an active ingredient and having remarkable hypoglycemic actions. CONSTITUTION:This extract from a leaf of Lagerstroemia speciosa is obtained by extracting a dried and pulverized leaf of the Lagerstroemia speciosa with hot water at 60-100 deg.C, preferably 95-IOOC, an organic solvent (e.g. methanol or ethanol) or a mixed solution of the organic solvent with hot water, then adsorbing the resultant crude extract on a styrene-divinylbenzene-based synthetic resin or a dextran-based synthetic resin, flowing distilled water therethrough, discharging the fraction unadsorbed on the resin and, on the other hand, eluting the ingredient adsorbed on the resin with an organic solvent. Thereby, the antidiabetic agent having more improved pharmacological effects than those of a crude extract is obtained by using the result extract from the adsorbed portion as an active ingredient. Remarkable hypoglycemic actions are recognized in the adsorbed fraction as compared with those of the unadsorbed fraction in tests using a mouse suffering from II type hereditary diabetes.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、フィリピンをはじめと
する東南アジア産のバナバ葉(Lagerstroemia speciosa
l. )から得られるバナバ葉抽出物及び抗糖尿病剤に関
する。
TECHNICAL FIELD The present invention relates to banaba leaves (Lagerstroemia speciosa) from Southeast Asia, including the Philippines.
l.) and an antidiabetic agent.

【0002】[0002]

【従来の技術】バナバは熱帯アジアに分布するミソハギ
科の植物で、別名オオバサルスベリと呼ばれている。古
くから原産地であるフィリピンでは、この葉を煎じて飲
用されて来た。しかし、一方ではバナバ葉が熱帯産のた
め、雑菌汚染がひどく、通常的に飲用するためには、十
分な殺菌操作が必要であった。
2. Description of the Related Art Banaba is a plant of the family Liliaceae that is distributed in tropical Asia, and is also known as Pleurotus cornucopia. In the Philippines, which is the place of origin for a long time, these leaves have been decocted and consumed. On the other hand, however, since Banaba leaves were produced in the tropics, they were heavily contaminated with various bacteria, and required a sufficient sterilization operation for normal drinking.

【0003】そこで従来、この主要成分を抽出するため
に、まずバナバ葉を粉砕した後、加熱殺菌処理をして、
これを直接乃至ティーバック等に詰めて、漢方薬と同じ
ように長時間煎じる方法が採られてきたが、このような
バナバ葉を煎じる抽出方法では、抽出条件が全く整備さ
れていないため均質的抽出が行い難く、また、一旦煎じ
た抽出液は腐敗しやすくそのままでは日持ちがしないた
め、毎日必要量を煎じる必要があり、非常に手間がかか
り面倒であった。
Therefore, conventionally, in order to extract this main component, first, banaba leaves were crushed and then heat-sterilized,
A method of brewing this directly or in tea bags and brewing for a long time as in the case of traditional Chinese medicine has been adopted. However, the extract once decocted is perishable and does not last as long as it is, so it is necessary to decoct the required amount every day, which is very troublesome and troublesome.

【0004】また、上記の飲用の薬効があることは、お
およそ知られていたが、その抗糖尿病有効成分について
は確認されておらず、純度の高い抗糖尿剤として工業的
に生産することは困難であった。
Although it has been generally known that the above-mentioned medicinal properties for drinking are effective, its antidiabetic active ingredient has not been confirmed, and it is difficult to industrially produce it as a highly pure antidiabetic agent. Met.

【0005】そこで、本発明者は、バナバ葉を熱水、有
機溶媒又は有機溶媒と熱水との混合溶液で抽出し、この
抽出溶液を濃縮し、乾燥させ、これを乾燥粉末とするこ
とにより、工業的に生産可能なバナバ葉抽出物エキスを
提案するとともに、このバナバ葉抽出物エキスの抗糖尿
病剤としての薬理効果を臨床的に確認している(特開平
5─310587)。
Therefore, the present inventor extracted banaba leaves with hot water, an organic solvent or a mixed solution of an organic solvent and hot water, concentrated the extract solution and dried it to obtain a dry powder. Proposed an industrially-produced Banaba leaf extract extract, and clinically confirmed the pharmacological effect of the Banaba leaf extract extract as an antidiabetic agent (Japanese Patent Laid-Open No. 5-310587).

【0006】[0006]

【発明が解決しようとする課題】本発明は、上記バナバ
葉抽出物に関する研究をさらに進めて為したものであ
り、本発明の目的とするところは、バナバ葉を熱水、有
機溶媒、又は有機溶媒と熱水との混合溶液で抽出して得
られた抽出物を更に分離精製することにより、抗糖尿病
効果が一層高く、かつ安全に使用することのできるバナ
バ葉抽出物及び抗糖尿病剤を得ることにある。
DISCLOSURE OF THE INVENTION The present invention has been made by further researching the above-mentioned banaba leaf extract. The object of the present invention is to remove banaba leaf from hot water, an organic solvent, or an organic solvent. By further separating and purifying the extract obtained by extraction with a mixed solution of a solvent and hot water, a banaba leaf extract and an antidiabetic agent that have a higher antidiabetic effect and can be safely used are obtained. Especially.

【0007】[0007]

【課題を解決するための手段】本発明では、バナバ葉を
熱水、有機溶媒又は有機溶媒と熱水との混合溶液で抽出
して得られた粗抽出物を、スチレン−ジビニルベンゼン
系合成樹脂又はデキストラン系合成樹脂に吸着させ、樹
脂吸着成分を有機溶媒で溶離させることにより、粗抽出
物から抗糖尿病効果の一層高いバナバ葉抽出成分を分離
精製することに成功した。また、この分離精製したバナ
バ葉抽出物を有効成分として抗糖尿病剤を得ることにも
成功した。
In the present invention, a crude extract obtained by extracting banaba leaves with hot water, an organic solvent or a mixed solution of an organic solvent and hot water is used as a styrene-divinylbenzene synthetic resin. Alternatively, by adsorbing onto a dextran-based synthetic resin and eluting the resin-adsorbed component with an organic solvent, a banaba leaf extract component having a higher antidiabetic effect was successfully separated and purified from the crude extract. In addition, we succeeded in obtaining an antidiabetic agent using the separated and purified Banaba leaf extract as an active ingredient.

【0008】本発明におけるバナバ葉抽出物は、乾燥し
粉砕したバナバ葉を、約60℃乃至100℃、好ましく
は沸点に近い温度乃至沸点すなわち95℃〜100℃の
熱水で抽出するか、有機溶媒例えばメタノール乃至エタ
ノールで抽出するか、有機溶媒と水との混合溶液で抽出
するか、或いは上記熱水抽出後の残渣をさらに有機溶媒
乃至有機溶媒と水との混合溶液で抽出するかして得るこ
とができる。このときの熱水、有機溶媒、又は有機溶媒
と水との混合溶液の量は、乾燥させたバナバ葉重量に対
して1:10乃至1:100、好ましくは1:25程度
となる量とする。
The banaba leaf extract according to the present invention is obtained by extracting dried and crushed banaba leaves with hot water at a temperature of about 60 ° C to 100 ° C, preferably close to or above the boiling point, that is, 95 ° C to 100 ° C. Either extraction with a solvent such as methanol or ethanol, extraction with a mixed solution of an organic solvent and water, or extraction of the residue after the above hot water extraction with a mixed solution of an organic solvent or an organic solvent and water is performed. Obtainable. At this time, the amount of hot water, the organic solvent, or the mixed solution of the organic solvent and water is 1:10 to 1: 100, preferably about 1:25 with respect to the weight of the dried banaba leaf. .

【0009】本発明におけるスチレン−ジビニルベンゼ
ン系合成樹脂としては、三菱化成工業(株)社製 DIAIO
N HP-10,20,30,40,50 、オルガノ(株)社製アンバーラ
イトXAD-2,4 、或いは住友化学工業(株)社製デュオラ
イトsシリーズなど、また、デキストラン系合成樹脂と
しては、ファルマシア社製Sephadex LH-20を使用するこ
とができる。なお、デキストラン系合成樹脂は、これを
構成するデキストラン鎖が三次元的に架橋された多糖類
的な編目を形成しているから、水酸基に対する炭素原子
数割合が比較的大きく、特にLH-20 は、デキストラン鎖
のグルコース単位毎にエーテル結合しているハイドロキ
シプロプル基を有しているから、特に大きい。従って、
デキストラン系合成樹脂ゲル、特にLH-20 は、親水性、
親油性の両方の性質を持ち、吸着性の点に関してみれ
ば、スチレン−ジビニルベンゼン系合成樹脂と同様と考
えることができる。しかしながら、現在のところ、経済
性の観点からみれば、スチレン−ジビニルベンゼン系合
成樹脂の方が優れている。
As the styrene-divinylbenzene synthetic resin in the present invention, DIAIO manufactured by Mitsubishi Kasei Co., Ltd.
N HP-10,20,30,40,50, Amberlite XAD-2,4 manufactured by Organo Co., or Duolite s series manufactured by Sumitomo Chemical Co., Ltd. , Sephadex LH-20 manufactured by Pharmacia can be used. Incidentally, the dextran-based synthetic resin, since the dextran chains constituting it form a three-dimensionally crosslinked polysaccharide-like stitch, the ratio of the number of carbon atoms to the hydroxyl group is relatively large, especially LH-20 In particular, since each glucose unit of the dextran chain has a hydroxypropyl group which is ether-bonded, it is particularly large. Therefore,
Dextran type synthetic resin gel, especially LH-20 is hydrophilic,
It has both lipophilic properties and can be considered to be similar to the styrene-divinylbenzene-based synthetic resin in terms of adsorptivity. However, at present, the styrene-divinylbenzene-based synthetic resin is superior from the economical point of view.

【0010】また、本発明の抗糖尿病剤は、バナバ葉を
約60℃乃至100℃の熱水又は有機溶媒で抽出して得
られた粗抽出物を、スチレン−ジビニルベンゼン系合成
樹脂又はデキストラン系合成樹脂に吸着させ、樹脂吸着
成分を有機溶媒で溶離させて得られるバナバ葉抽出物を
有効成分として得ることができ、その抗糖尿病作用は糖
尿病マウスを用いた動物試験によって確認することがで
きた。
The antidiabetic agent of the present invention is a styrene-divinylbenzene-based synthetic resin or dextran-based resin obtained by extracting a crude extract obtained by extracting banaba leaves with hot water at about 60 ° C to 100 ° C or an organic solvent. Banaba leaf extract obtained by adsorbing to a synthetic resin and eluting the resin-adsorbed component with an organic solvent can be obtained as an active ingredient, and its antidiabetic effect could be confirmed by an animal test using diabetic mice. .

【0011】[0011]

【実施例】【Example】

〔製造方法〕フィリピン産バナバの生葉を適宜量自然乃
至強制的に十分に乾燥させ、これを粉砕器で粉砕し、よ
く混合したバナバ葉1kgを50リットル前後の蒸留水
で30分間前後、95〜100℃で抽出した。得られた
抽出液を濾過後、遠心分離させた後、更にエバポレータ
で濃縮させ、凍結乾燥或いはスプレードライ等の方法に
より乾燥させて粗抽出物(バナバ葉抽出エキス)を得
た。このとき、粗抽出物の収率は、乾燥バナバ葉(原
料)に対して約10%(W/W) であった。
[Production method] Fresh leaves of Philippine Banaba are dried naturally or forcibly and adequately and then crushed with a crusher. 1 kg of well-mixed Banaba leaves is squeezed in about 50 liters of distilled water for about 30 minutes. Extracted at 100 ° C. The obtained extract was filtered, centrifuged, and then concentrated by an evaporator and dried by a method such as freeze-drying or spray-drying to obtain a crude extract (banaba leaf extract). At this time, the yield of the crude extract was about 10% (W / W) based on the dried banaba leaf (raw material).

【0012】次に、直径10cm、長さ100cmのガ
ラスカラムにスチレン−ジビニルベンゼン系合成樹脂
(製品名:三菱化成工業(株)社製 DIAION HP-20 )を
2.5リットル充填し、この充填剤をメタノールで洗浄
しさらに蒸留水で洗浄した後、上記粗抽出物(全量)を
1リットルの蒸留水に溶かしてこれをガラスカラム内に
流した。その後、カラム容量に対して約6倍量相当の蒸
留水を流してスチレン−ジビニルベンゼン系合成樹脂に
吸着されなかった分画(以下、非吸着分画とする)を流
出させる一方、カラム容量に対して約5倍量相当の10
0%メタノールを流してスチレン−ジビニルベンゼン系
合成樹脂に吸着された分画(以下、吸着分画とする)を
溶出させた。こうして得られた非吸着分画及び吸着分画
はそれぞれ、濃縮し、凍結乾燥或いはスプレードライ等
の方法により乾燥させて、乾燥粉末として得た。このと
きの収率は、乾燥バナバ葉(原料)に対して、非吸着分
画が約4.3%、吸着分画が約2.7%であった。
Next, 2.5 liters of a styrene-divinylbenzene synthetic resin (product name: DIAION HP-20 manufactured by Mitsubishi Kasei Co., Ltd.) was filled in a glass column having a diameter of 10 cm and a length of 100 cm, and this filling was performed. After the agent was washed with methanol and further washed with distilled water, the crude extract (total amount) was dissolved in 1 liter of distilled water, and this was poured into a glass column. Then, about 6 times as much distilled water as the column volume was flowed to flow out the fraction not adsorbed on the styrene-divinylbenzene-based synthetic resin (hereinafter referred to as non-adsorbed fraction), while 10 times the equivalent of about 5 times
A fraction adsorbed on the styrene-divinylbenzene-based synthetic resin (hereinafter referred to as an adsorption fraction) was eluted by flowing 0% methanol. The non-adsorbed fraction and the adsorbed fraction thus obtained were concentrated and dried by a method such as freeze-drying or spray-drying to obtain a dry powder. The yields at this time were about 4.3% for the non-adsorbed fraction and about 2.7% for the adsorbed fraction based on the dried banaba leaf (raw material).

【0013】〔抗糖尿病剤作用試験〕II型遺伝性糖尿病
マウスを用いて、バナバ葉抽出物の抗糖尿病剤作用試験
について、以下のように試験した。
[Antidiabetic agent action test] Using a type II hereditary diabetic mouse, an antidiabetic action test of banaba leaf extract was tested as follows.

【0014】被検試料として、上記製造方法で得た吸着
分画及び非吸着分画を用い、実験動物として、KKAy
a c1マウス(II型遺伝性糖尿病マウス)を用いた。
The adsorbed fraction and the non-adsorbed fraction obtained by the above-mentioned production method were used as test samples, and KKA y was used as an experimental animal.
T a J c1 mice (type II inherited diabetic mice) were used.

【0015】II型遺伝性糖尿病マウス(4週齢)を基本
食(ガゼイン25.0%(W/W)(以下%(W/W) 省略) ,塩
混合物3.5,ビタミン混合物1.0,ビタミンC及び
ビタミンK0.2,塩化コリン0.2,コーン油5.
0,砂糖51.0,デンプン(α)14.1)で1週間
飼育後、1群7匹毎の三群に分け、一群には、上記基本
食にその5.0%(W/W) 相当量のセルロースを添加した
食餌を投与して対象群とし、他の一群には、上記基本食
にその2.0%(W/W) 相当量の吸着分画を添加した食餌
を投与し(以下、「吸着分画群」とする)、さらに他の
一群には、上記基本食にその3.0%(W/W) 相当量の非
吸着分画を添加した食餌を投与し(以下、「非吸着分画
群」とする)、それぞれ6週間飼育した。なお、食餌は
経口投与した。
Type II hereditary diabetic mice (4 weeks old) were fed a basic diet (gasein 25.0% (W / W) (hereinafter% (W / W) omitted), salt mixture 3.5, vitamin mixture 1.0. , Vitamin C and vitamin K 0.2, choline chloride 0.2, corn oil 5.
After breeding for 1 week with 0, sugar 51.0, starch (α) 14.1), it was divided into 3 groups of 7 animals per group, and 1 group contained 5.0% (W / W) of the above basic diet. A diet to which a considerable amount of cellulose was added was used as a target group, and to the other group, a diet to which an adsorbed fraction equivalent to 2.0% (W / W) thereof was added to the above basic diet was administered ( Hereinafter, referred to as "adsorption fraction group"), to yet another group, a diet prepared by adding a non-adsorption fraction equivalent to 3.0% (W / W) to the above basic diet (hereinafter, "Non-adsorbed fraction group"), and each was bred for 6 weeks. The diet was orally administered.

【0016】飼育前及び飼育中のマウスの体重、飼料摂
取量及び飲水量を測定し、その結果を表1に示した。ま
た、一週毎にマウスの尾静脈血を採取して血糖値を定量
し、その結果を表2及び図1に示した。なお、結果の統
計処理は、Student-t 検定で行った。
The body weight, feed intake and water intake of the mice before and during the rearing were measured, and the results are shown in Table 1. Further, tail vein blood of the mouse was collected every week to quantify the blood glucose level, and the results are shown in Table 2 and FIG. The results were statistically processed by Student-t test.

【0017】[0017]

【表1】 [Table 1]

【0018】[0018]

【表2】 [Table 2]

【0019】表1より、体重増加量及び飼料摂取量に関
しては、各群間に有意差を認めることはできなかった
が、血糖値に関しては、表2及び図1より、吸着分画群
と対象群との間に明らかな有意差を認めることができ
た。また、この血糖上昇抑制作用は週の経過とともに顕
著になっていることも認められた。
From Table 1, there was no significant difference in weight gain and feed intake between the groups, but in regard to blood glucose level, from Table 2 and FIG. A clear significant difference could be seen between the groups. In addition, it was also confirmed that this blood glucose elevation inhibitory effect became more prominent over the course of the week.

【0020】よって、吸着分画の血糖上昇抑制作用が、
非吸着分画の作用よりも有意に優れていることを確かめ
ることができ、これより、バナバ葉粗抽出物から上記吸
着分画を抽出すれば、抗糖尿病効果の一層高い成分を分
離精製することができることが明らかとなった。また、
糖尿病の発症が見られ始める頃から吸着分画を含む食餌
を投与すれば、十分な血糖上昇抑制効果を得ることがで
きることも判明した。
Therefore, the adsorbed fraction suppresses the increase in blood glucose.
It can be confirmed that it is significantly superior to the action of the non-adsorbed fraction, and from this, if the above-mentioned adsorbed fraction is extracted from the banaba leaf crude extract, it is possible to separate and purify components having a higher antidiabetic effect. It became clear that Also,
It was also found that when a diet containing an adsorbed fraction is administered from the time when the onset of diabetes is observed, a sufficient blood glucose elevation suppressing effect can be obtained.

【0021】〔有効量〕表1より、マウス(吸着分画
群)7匹が一週間当たりに摂取する飼料量は29.5g
である。これよりマウス一匹、一日当たり約0.012
gの吸着分画を摂取すれば十分であり、さらにマウスの
平均体重が約22gであることからして、マウスは1日
・体重1kg当たり約0.55gの吸着分画を摂取すれ
ば、十分な抗糖尿病作用効果を得ることができる。しか
しながら、ヒトの感受性はマウスのそれに比べて高いの
で、吸着分画をヒトに投与する場合には、上記マウスに
対する投与量の10分の1乃至100分の1の体重割合
による量で十分足りるものと推定される。
[Effective amount] As shown in Table 1, the amount of feed consumed by 7 mice (adsorption fraction group) per week was 29.5 g.
Is. From this, one mouse is about 0.012 per day
It is sufficient to ingest the adsorbed fraction of g, and since the average weight of the mouse is about 22 g, it is sufficient for the mouse to ingest the adsorbed fraction of about 0.55 g per 1 kg of body weight per day. It is possible to obtain various antidiabetic action effects. However, since human sensitivity is higher than that of mice, when the adsorbed fraction is administered to humans, a dose of 1/10 to 1/100 of the dose for mice is sufficient. It is estimated to be.

【0022】〔毒性試験〕II型遺伝性糖尿病マウスに対
して、上記基本食に上記製造方法と同様にして得た粗抽
出物を基本食の5%(W/W) 相当量添加した食餌を6週間
連続して経口投与して観察を行ったところ、投与中及び
投与後もマウスに副作用は認められなかった。
[Toxicity test] To a type II hereditary diabetic mouse, a diet prepared by adding a crude extract obtained in the same manner as in the above production method to the above basic diet in an amount equivalent to 5% (W / W) of the basic diet was used. When observed orally for 6 consecutive weeks, no side effects were observed in the mice during and after the administration.

【0023】[0023]

【発明の効果】本発明により、バナバ葉を熱水、有機溶
媒、又は有機溶媒と熱水との混合溶液で抽出して得られ
た粗抽出物を、さらにスチレン−ジビニルベンゼン系合
成樹脂又はデキストラン系合成樹脂に吸着させ、樹脂吸
着成分を有機溶媒で溶出することにより、バナバ葉粗抽
出成分中から抗糖尿病効果のより一層優れた成分を分離
精製することができる。これにより、薬理効果の一層優
れた抗糖尿病剤を得ることに成功した。
According to the present invention, a crude extract obtained by extracting banaba leaves with hot water, an organic solvent, or a mixed solution of an organic solvent and hot water is further added to a styrene-divinylbenzene synthetic resin or dextran. By adsorbing the resin-adsorbed component on the system synthetic resin and eluting the resin-adsorbed component with an organic solvent, a component having a more excellent antidiabetic effect can be separated and purified from the crude banaba leaf extract component. As a result, we succeeded in obtaining an antidiabetic agent having a more excellent pharmacological effect.

【0024】本発明の抗糖尿病剤は、少なくとも糖尿病
の症状が見られ始める頃から投与すれば、十分に薬理効
果を発揮させることができる。その安全性に関しては、
フィリピンなどで旧くからバナバを煎じた茶を常飲して
いることからも明らかであるが、上記毒性試験によって
も確かめることができる。
The antidiabetic agent of the present invention can exert a sufficient pharmacological effect when it is administered at least when the symptoms of diabetes are observed. Regarding its safety,
It can be confirmed by the toxicity test described above, although it is clear from the fact that teas from which banaba is brewed for a long time have been always consumed in the Philippines and the like.

【0025】また、本発明のバナバ葉抽出物は、オート
クレーブ殺菌し、凍結例えば凍結乾燥してバナバ葉抽出
粉末エキスとすれば、飲用可能な適当な濃度に希釈し、
缶ドリンク、瓶ドリンクにして飲み安くする事もできる
し、また、タブレット、カプセル状、顆粒状などに成形
して医薬品又は準医薬品とすることもできる。さらに
は、他の生薬類あるいはジュース類と混合して特殊栄養
食品乃至特殊栄養飲料とすることもできる。このとき、
バナバ葉抽出物を濃度調整し、容器に詰めた後に、これ
をレトルト殺菌、又はこの抽出液のPHを4.6未満に
調整して中心部の温度を約85℃で10分間加熱する方
法等により殺菌処理すれば、食品衛生法に定められた条
件下で殺菌した上で提供することができる。
The banaba leaf extract of the present invention is sterilized by autoclaving and frozen, for example, freeze-dried to obtain a banaba leaf extract powder extract, which is diluted to an appropriate concentration for drinking,
It can be made into canned drinks and bottled drinks to be cheaply drinkable, or it can be molded into tablets, capsules, granules or the like to prepare pharmaceuticals or semi-pharmaceuticals. Further, it can be mixed with other crude drugs or juices to prepare a special nutrition food or a special nutrition drink. At this time,
After adjusting the concentration of the Banaba leaf extract and packing it in a container, it is retort sterilized, or the pH of this extract is adjusted to less than 4.6 and the center temperature is heated at about 85 ° C for 10 minutes, etc. If sterilized by the method described above, it can be provided after being sterilized under the conditions specified by the Food Sanitation Law.

【図面の簡単な説明】[Brief description of drawings]

【図1】本発明に係わるバナバ葉抽出物の血糖効果作用
を示したグラフである。
FIG. 1 is a graph showing the blood sugar effect of the Banaba leaf extract according to the present invention.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 川崎 年夫 静岡県榛原郡相良町女神21 株式会社伊藤 園中央研究所内 (72)発明者 竹内 久直 静岡県静岡市大谷2787−34 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Toshio Kawasaki 21 Goddess Sagara-cho, Haibara-gun, Shizuoka Prefecture Itoen Central Research Institute (72) Inventor Hisao Nao Takeuchi 2787-34 Otani, Shizuoka-shi

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 バナバ葉を約60℃乃至100℃の熱
水、有機溶媒、又は有機溶媒と熱水との混合溶液で抽出
して得られた粗抽出物を、スチレン−ジビニルベンゼン
系合成樹脂又はデキストラン系合成樹脂に吸着させ、樹
脂吸着成分を有機溶媒で溶離させて得られるバナバ葉抽
出物。
1. A styrene-divinylbenzene-based synthetic resin comprising a crude extract obtained by extracting banaba leaves with hot water at about 60 ° C. to 100 ° C., an organic solvent, or a mixed solution of an organic solvent and hot water. Alternatively, a banaba leaf extract obtained by adsorbing it on a dextran-based synthetic resin and eluting the resin-adsorbing component with an organic solvent.
【請求項2】 請求項1記載の樹脂吸着成分を有効成分
とする抗糖尿病剤。
2. An antidiabetic agent comprising the resin adsorbing component according to claim 1 as an active ingredient.
JP02151094A 1994-02-18 1994-02-18 Banaba leaf extract and antidiabetic agent Expired - Fee Related JP3507115B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP02151094A JP3507115B2 (en) 1994-02-18 1994-02-18 Banaba leaf extract and antidiabetic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP02151094A JP3507115B2 (en) 1994-02-18 1994-02-18 Banaba leaf extract and antidiabetic agent

Publications (2)

Publication Number Publication Date
JPH07228539A true JPH07228539A (en) 1995-08-29
JP3507115B2 JP3507115B2 (en) 2004-03-15

Family

ID=12056976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP02151094A Expired - Fee Related JP3507115B2 (en) 1994-02-18 1994-02-18 Banaba leaf extract and antidiabetic agent

Country Status (1)

Country Link
JP (1) JP3507115B2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981510A (en) * 1997-04-15 1999-11-09 Yaizu Suisankagaku Industry Co., Ltd. Method for treating and improving diabetes
EP1055428A1 (en) * 1999-05-25 2000-11-29 USE Techno Corporation Liquid composition to be vaporized for inhibiting increase in blood sugar level, vaporizer for the same and use of the same
EP1166790A1 (en) * 2000-06-28 2002-01-02 Ito En, Ltd. Sugar decomposition inhibitor, digestive enzyme activity inhibitor, insulin secretion controller, and healthy food and beverage
US6716459B2 (en) * 1998-12-09 2004-04-06 Futoshi Matsuyama Composition for inhibiting increase of blood sugar level or lowering blood sugar level
EP1427429A4 (en) * 2001-08-31 2006-11-02 Univ Ohio Compositions and methods for treating subjects with hyperglycemia
WO2013100718A3 (en) * 2011-12-30 2013-08-22 한국생명공학연구원 Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient
CN114869923A (en) * 2022-06-14 2022-08-09 大理大学 National medicine double ginseng water-soluble extract and preparation method and application thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100901379B1 (en) * 2006-07-10 2009-06-05 주식회사 삼양제넥스 Method for separation and purification of corosolic acid from corosolic acid-containing materials

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981510A (en) * 1997-04-15 1999-11-09 Yaizu Suisankagaku Industry Co., Ltd. Method for treating and improving diabetes
US6242431B1 (en) 1997-04-15 2001-06-05 Yaizu Suisankagaku Industry Co., Ltd. Method for treating liver dysfunction
US6716459B2 (en) * 1998-12-09 2004-04-06 Futoshi Matsuyama Composition for inhibiting increase of blood sugar level or lowering blood sugar level
EP1055428A1 (en) * 1999-05-25 2000-11-29 USE Techno Corporation Liquid composition to be vaporized for inhibiting increase in blood sugar level, vaporizer for the same and use of the same
EP1166790A1 (en) * 2000-06-28 2002-01-02 Ito En, Ltd. Sugar decomposition inhibitor, digestive enzyme activity inhibitor, insulin secretion controller, and healthy food and beverage
EP1427429A4 (en) * 2001-08-31 2006-11-02 Univ Ohio Compositions and methods for treating subjects with hyperglycemia
WO2013100718A3 (en) * 2011-12-30 2013-08-22 한국생명공학연구원 Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient
CN104185473A (en) * 2011-12-30 2014-12-03 韩国生命工学研究院 Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient
EP2799082A4 (en) * 2011-12-30 2015-07-15 Korea Res Inst Of Bioscience Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient
US9610310B2 (en) 2011-12-30 2017-04-04 Korea Research Institute Of Bioscience And Biotechnology Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient
CN114869923A (en) * 2022-06-14 2022-08-09 大理大学 National medicine double ginseng water-soluble extract and preparation method and application thereof
CN114869923B (en) * 2022-06-14 2023-09-01 大理大学 Water-soluble extract of national medicine double ginseng, preparation method and application thereof

Also Published As

Publication number Publication date
JP3507115B2 (en) 2004-03-15

Similar Documents

Publication Publication Date Title
KR101370841B1 (en) Guava leaf extract powder and method for production thereof
JP5937596B2 (en) Urushi extract with increased content of active flavonoid compound and method for producing the same
JP4678904B2 (en) Weight gain inhibitor from hops
TWI239245B (en) Medical composition for oral administration or intravenous administration for a disease requiring enhancement of nerve growth factor production for treatment or prevention
WO2007102439A1 (en) Fractionation product of aqueous extract of eucommia ulmoides oliver leaf, and composition for oral ingestion comprising the fractionation product
TW201340977A (en) Des(rhamnosyl) acteoside-containing olive extract
JP3507115B2 (en) Banaba leaf extract and antidiabetic agent
JP2015502954A (en) A composition for preventing or treating dyslipidemia, comprising an aqueous extract of Aguitake as an active ingredient
WO2007102438A1 (en) Fractionation product of aqueous extract of eucommia ulmoides oliver leaf, and anti-obesity agent comprising the fractionation product
KR102315959B1 (en) A composition for reinforcing immune function comprising the extract of oat sprout
KR20160141027A (en) Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder
CN109602759B (en) Application of podocarpus macrophyllus polysaccharide
CN106581115B (en) Composition containing yuankanin and ginseng and application thereof
JPH05310587A (en) Extract of banaba leaf, its use and antidiabetic agent
WO2018151334A1 (en) Xanthine oxidase inhibitor and method for producing same
JP2011072227A (en) New beverage
JP3507116B2 (en) Cholesterol elevation inhibitor
KR20160066643A (en) Anti-diabetic composition containing the extract of actinidia arguta leaves or fractions thereof
KR101910099B1 (en) Compositions for improving lipid metabolism or anti-obesity as an active ingredient extracted from an immature persimmon by pressurized hydrothermal method
KR101344676B1 (en) Composition for preventing and treating obesity comprising Angelica Keiskei Koid. extract
TW200407317A (en) Enterokinesis promoting ingesta
CN105963330A (en) Miracle fruit preparation and application thereof
JP4580447B2 (en) Agaricus-containing composition
KR102467837B1 (en) Composition comprising radish sprouts extract including increased isothiocyanate and method for preparing the same
JP6812032B2 (en) Luo Han Guo extract

Legal Events

Date Code Title Description
A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20031218

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121226

Year of fee payment: 9

LAPS Cancellation because of no payment of annual fees